Search results
Showing 31 to 34 of 34 results for prostatic hyperplasia
This guidance has been updated and replaced by NICE interventional procedures guidance 737.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE interventional procedures guidance 770.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.